Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy
Dateline City: KENILWORTH, N.J. Results from C-EDGE CO-STAR Presented at The Liver Meeting® Show High Sustained Virologic Response After 12 Weeks of Treatment KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the company’s Phase 3 C-EDGE CO-STAR clinical trial evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection who inject drugs and are receiving opioid agonist therapy (OAT). Language: English Contact: MerckMedia Contacts:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
We present two cases of immunosuppressed patients diagnosed with acute hepatitis C (AHC) HCV-antibody negative by HCV-RNA testing. Delayed seroconversion in immunosuppressed patients may result in retarded diagnosis and treatment. Therefore, HCV-RNA testing should be part of the initial evaluation. PMID: 30896958 [PubMed - as supplied by publisher]
(Institute for Operations Research and the Management Sciences) There are currently more than three million people in the US with hepatitis C, a condition that can lead to serious and even deadly liver complications. In the US prison system, the prevalence of hepatitis C virus (HCV) infection is currently 10 times higher than the national average. However, new research in the INFORMS journal Operations Research, has identified new protocols that could substantially decrease HCV infection in the US prison system.
ConclusionsInitial and re-treatment with GLE/PIB are effective and safe for Japanese patients with HCV-1/2/3 in real-life settings. Further studies are required to elucidate the mechanism underlying treatment failures of GLE/PIB to completely eradicate HCV worldwide.
ConclusionsThis qualitative study uncovered several unanticipated determinants of HCV treatment completion and provides rationale for several targeted interventions such as incorporating structured positive reinforcement.
AbstractIntroductionHepatitis C virus (HCV) displays high genetic diversity, characterized by regional variations in the prevalence of genotype posing challenges to the development of vaccines and definitive treatment. Very few reports exist on the distribution and frequency change of HCV genotypes in India. In the present retrospective study, we aimed to understand the distribution pattern of HCV genotypes and viral load among HCV-infected patients attending the Asian Institute of Gastroenterology, Hyderabad, India, a tertiary care hospital.MethodsPatients referred to the Hepatology Department from January 2009 to Decembe...
Background: Veterans with hepatitis C virus (HCV) infection may face geographic obstacles to obtaining treatment. Objective: We studied the influence of region and rural versus urban residence on receipt of direct-acting antiretroviral (DAA) medications for HCV. Subjects: Veterans receiving care within Veterans Affairs Healthcare System born between 1945 and 1965. Research Design: This is a observational study using national electronic health record data. Measures: Receipt of DAAs was defined as ≥1 filled prescription from January 1, 2014 to December 31, 2016. Region (South, Northeast, Midwest, and West) a...
Authors: Verhelst X, Devolder G, De Wilde M, Goderis L, De Bel A, Spillebeen E, Geerts A, Derese A, Van Vlierberghe H PMID: 30888763 [PubMed - in process]
We report here three cases of patients transplanted for hepatocellular carcinoma on HCV-related cirrhosis. All cases experienced an acute cellular rejection after the end of HCV therapy with direct acting antivirals (DAAs). We thus advocate for a close monitoring of tacrolimus and liver tests even a few months after the end of the treatment. Clinicians using DAAs after liver transplantation should be aware of the dynamics of tacrolimus levels during therapy and immunological changes that can occur even several weeks (or months) after the end of DAA treatment. PMID: 30888754 [PubMed - in process]
CONCLUSIONS: This study provides recent data on the CHC patient population and disease characteristics in Belgium that could help medical communities and government agencies manage CHC disease burden. PMID: 30888753 [PubMed - in process]
CONCLUSIONS: This study supports the need of a continued effort of health care providers to identify people infected with HCV. For a population at risk such as people who use drugs, regular screening is needed to reach the goal set by WHO of near viral elimination of HCV by 2030. PMID: 30888752 [PubMed - in process]